Research graph
References from Levonorgestrel-ethinyl estradiol impairs hepatic lipid clearance to induce hypercholesterolemia via PCSK9-mediated LDLR and CD36 dysregulation. Local targets link to admitted publications; unresolved targets remain external evidence.
Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism
10.3109/13625187.2011.604450 · 2011 · External reference
Hypertriglyceridemia-induced acute pancreatitis exacerbated by combined oral contraceptive use: a case report
2024 · External reference
Oral contraceptives in adolescents: a retrospective population-based study on blood pressure and metabolic dysregulation
10.1007/s00228-024-03671-z · 2024 · External reference
PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver
10.1161/atvbaha.115.306032 · 2015 · External reference
Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome
2020 · External reference
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021
10.1016/s0140-6736(24)00367-2 · 2024 · External reference
CD36 as a gatekeeper of myocardial lipid metabolism and therapeutic target for metabolic disease
10.1152/physrev.00011.2023 · 2024 · External reference
PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling
10.1161/circulationaha.124.072336 · 2025 · External reference
CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis
10.1038/s41467-020-18565-8 · 2020 · External reference
Association between oral contraceptives with lipid profile: results from Hoveyzeh cohort study (HCS)
10.1186/s12905-023-02703-7 · 2023 · External reference
Targeting PCSK9 to tackle cardiovascular disease
10.1016/j.pharmthera.2023.108480 · 2023 · External reference
CD36 as a double-edged sword in cancer
10.1016/j.imlet.2023.12.002 · 2024 · External reference
Proprotein convertase subtilisin/Kexin 9 (PCSK9) promotes macrophage activation via LDL receptor-independent mechanisms
10.1161/circresaha.121.320056 · 2022 · External reference
Effect of second and third generation oral contraceptives on C-reactive protein, lipids and apolipoproteins in young, non-obese, non-smoking apparently healthy women
10.1016/j.clinbiochem.2009.12.013 · 2010 · External reference
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
10.1097/mol.0000000000000114 · 2014 · External reference
The changing landscape of atherosclerosis
10.1038/s41586-021-03392-8 · 2021 · External reference
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
10.1093/eurheartj/ehz455 · 2020 · External reference
CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD
10.1681/asn.2008010009 · 2009 · External reference
2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults
2021 · External reference
The interplay of lipids, lipoproteins, and immunity in atherosclerosis
10.1007/s11883-018-0715-0 · 2018 · External reference
Inclisiran for the treatment of heterozygous familial hypercholesterolemia
10.1056/nejmoa1913805 · 2020 · External reference
World heart federation cholesterol roadmap 2022
10.5334/gh.1154 · 2022 · External reference
Evolocumab and clinical outcomes in patients with cardiovascular disease
10.1056/nejmoa1615664 · 2017 · External reference
Fatty acid transport and signaling: mechanisms and physiological implications
10.1146/annurev-physiol-032122-030352 · 2023 · External reference
Alirocumab and cardiovascular outcomes after acute coronary syndrome
10.1056/nejmoa1801174 · 2018 · External reference
The role of CD36 in cardiovascular disease
10.1093/cvr/cvaa319 · 2022 · External reference
PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort
10.1371/journal.pone.0239752 · 2020 · External reference
PCSK9: a multi-faceted protein that is involved in cardiovascular biology
2021 · External reference
Dyslipidemia and associated factors among women using hormonal contraceptives in Harar town, Eastern Ethiopia
10.1186/s13104-019-4148-9 · 2019 · External reference
Glucose-dependent insulinotropic polypeptide inhibits AGE-induced NADPH oxidase-derived oxidative stress generation and foam cell formation in macrophages partly via AMPK activation
10.3390/ijms25179724 · 2024 · External reference
DHHC4 and DHHC5 facilitate fatty acid uptake by palmitoylating and targeting CD36 to the plasma membrane
10.1016/j.celrep.2018.12.022 · 2019 · External reference
2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution set Oversight Committee
10.1016/j.jacc.2022.07.006 · 2022 · External reference
CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis
10.1016/j.jhep.2018.04.006 · 2018 · External reference
